Recent Updates
Recently added Catalysts
Avoro Capital Advisors 13F Holdings (Q2 2026)
According to its SEC 13F filed on Aug 14, 2026, Avoro Capital Advisors reported 26 long positions worth $11.14B as of Jun 30, 2026. UTHR is 13.5% of the portfolio and the top 10 holdings are 79%. Against Q1 2026 it opened 2 new positions, added to 12, trimmed 3 and exited 8. 6 holdings have a dated FDA decision or data readout in the next 90 days, and 10 more expect one in a stated window such as "H2 2026".
Catalysts ahead in this portfolio
Dated FDA decisions and data readouts for its holdings in the next 90 days, with our probability of approval
4 more with a subscription
What changed vs Q1 2026
Full lists with a subscription
Portfolio over time
13F value by quarter, Q1 2021 to Q2 2026
By company stage (share of value)
Holdings
Every position in the 13F, with the change since the fund's previous filing, how many of the 45 specialist funds also own it, and its next FDA catalyst. Option positions are labelled CALL or PUT.
| Stock | Company Name | Shares Held | Market Value | % of Portfolio | QoQ Change | Position Change | Also Held By | Stage | Next Catalyst |
|---|---|---|---|---|---|---|---|---|---|
 DFTX | DEFINIUM THERAPEUTICS INC | 7.19 M | 338.17 M | 3 | Added +44% | Clinical | Expected 2026 Phase 2a data readout | ||
 COAG | HEMAB THERAPEUTICS HLDGS INC | 1.93 M | 70.71 M | 0.6 | New | Clinical | None in 90 days | ||
 QURE | UNIQURE NV | 6.73 M | 309.88 M | 2.8 | Added +13% | Clinical | None in 90 days | ||
 SEPN | SEPTERNA INC | 1.34 M | 44.79 M | 0.4 | Unchanged | Clinical | None in 90 days | ||
 FTH | FAETH THERAPEUTICS INC | 1.44 M | 36.10 M | 0.3 | New | Clinical | Expected H2 2026 Phase 2 topline data readout | ||
 KYMR | KYMERA THERAPEUTICS INC | 7.47 M | 857.13 M | 7.7 | Unchanged | Clinical | Nov 6, 2026 Pre-clinical data presentation |
Top 20 Holdings
Size = share of the portfolio. Option positions show CALL or PUT.
Who else owns these stocks?
All Stock Holdings ranks every biotech stock by how many of the 45 specialist funds own it, and whether that number rose or fell this quarter. Click "of 45 funds" on any row above, or open the full view.
Questions about Avoro Capital Advisors's 13F
What does Avoro Capital Advisors own?
26 stocks worth $11.14B at Jun 30, 2026, as reported in its 13F, led by UTHR (13.5% of the portfolio). The full list is in the Holdings table above.
What did it buy and sell last quarter?
Against Q1 2026: 2 new positions, 12 increases, 3 reductions and 8 full exits, from its 13F filings.
How current is this data?
13F filings are due 45 days after each quarter ends, so they show positions at quarter end, not today. The next filing (Q3 2026) is due Nov 16, 2026.
Why are some positions labelled CALL or PUT?
Those are option positions (calls and puts). The 13F reports them as the shares underlying the option, with no strike or expiry, so they are listed apart from share positions.
Source: SEC EDGAR Form 13F-HR filed by Avoro Capital Advisors LLC, accession 0001104659-26-096427, filed Aug 14, 2026. Values as filed; option positions are shown at the value of the underlying shares and labelled CALL or PUT.